Here’s what you should know:
1. A research team will attempt to develop advanced translational disease models through the use of IBD patient tissue samples.
2. The samples will facilitate SCG’s high quality chemical probe testing, along with several of Takeda’s compounds.
3. Researchers hope the testing will allow for the interrogation of unexplored cellular targets and pathways in “these diseases of substantial need.”
4. Takeda will fund the research for three years and will make all research available to the parties without restriction on use.
5. Takeda will exclusively own the study’s outcomes and will link patients to drug candidates, identify new patient subpopulations or assess underlying biological mechanisms.
More articles on gastroenterology:
GI center to know: Phoenix Endoscopy
Award winners, new hires & more: 6 GI practices in the news
Undergoing colonoscopy ups appendicitis risk 1 week after — 4 key notes
